Rick Vreman holds a PhD within the field of Health Technology Assessment. Currently he works as an assistant professor at Utrecht University, the Netherlands and as an advisor at the Dutch National Health Care Institute (ZIN). His work focuses on bridging the worlds of drug evidence generation, authorization and (inter)national reimbursement systems through policy analyses and the development of innovative health economic methodologies. His focus lies specifically on innovative drugs addressing high unmet medical and societal needs.